Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.
Dapagliflozin cuts HbA1c in paediatric T2D
17 Oct 2023First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.
First-line therapies for advanced NSCLC improve survival, QoL
16 Oct 2023Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
16 Oct 2023Lotilaner drops proven safe, effective in Demodex blepharitis
Treatment with lotilaner ophthalmic solution 0.25% twice daily for 6 weeks is well tolerated by patients with Demodex blepharitis and has no serious adverse effects compared to a vehicle control, according to a study. Moreover, use of this drop results in clinically meaningful outcomes.
Lotilaner drops proven safe, effective in Demodex blepharitis
15 Oct 2023COVID-19 vaccination possibly linked to menstrual abnormalities
A high incidence of menstrual disorders among women aged ≤54 years has been noted following COVID-19 vaccination, reveals a Netherlands study. Analysis of spontaneous reports supports this observation.
COVID-19 vaccination possibly linked to menstrual abnormalities
14 Oct 2023Water vapor thermal therapy for moderate, severe BPH offers most bang for the buck
In the treatment of moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore, water vapor thermal therapy (WVTT) is more cost effective than medical management (MM) in the first-line setting based on the common willingness-to-pay threshold of SGD 50,000 per quality-adjusted life-years (QALYs), a study has found.